Tag: genomics
-
Zika DNA Vaccine Begins Clinical Trial
A new clinical trial is underway testing a Zika vaccine that uses genetically-engineered DNA to generate an immune response against the disease.
-
Start-Up Licensing Flexible Genome-Editing Technology
A start-up biotechnology company is licensing techniques from two universities that make genome editing more flexible and better control gene expression.
-
Climate-Resistant Oilseed Crop Plant Developed
An academic-industry team developed a new crop plant variety that produces cooking oil like rapeseed or canola, but in a warmer and dryer climate.
-
Univ. of California to Gain European Crispr-Cas9 Patent
A patent dispute among top research universities took another turn, as the European Patent Office announced its intention to grant a patent to University of California for its genome editing techniques.
-
Genetic Techniques Speed Brain, Muscle Cell Production
A new technology targets the expression of genes in stem cells to produce specific brain and muscle cells on demand and in a few days, a fraction of the time now required.
-
Regeneron to Sequence 500K UK Biobank Genomes
A biotech company and health database center are partnering with drug maker GlaxoSmithKline to produce genomic data on 500,000 individuals for drug discovery.
-
Trial to Test Gene Therapy for Inherited Eye Disease
A spin-off enterprise from University of Oxford in the U.K. began enrolling participants in a clinical trial testing gene therapy to correct a genetic eye disease.
-
Heart Assoc, Amazon Partner on Precision Medicine Data
American Heart Association and Amazon Web Services are collecting data from researchers to advance precision medicine in cardiovascular diseases and stroke.
-
Organ Transplant Start-Up Gains $38M in Early Funds
A one year-old company applying genome editing to make animal organs fit for human transplantation is raising $38 million its first venture funding round.
-
Allergan to Option Gene Editing for Eye Diseases
International drug maker Allergan is gaining access to treatments for inherited eye diseases being developed by Editas Medicine, a spin-off enterprise from MIT and Harvard.